Prof. PeptideProf. Peptide

November 7, 2026

Is CagriSema Better Than Semaglutide? A Type 2 Diabetes Meta-Analysis Finds the Edge Is Weight, Not Blood Sugar

In type 2 diabetes, CagriSema lowered body weight more than semaglutide alone, but its extra effect on blood sugar was too small to separate from zero. That is the finding of a Bayesian meta-analysis of six randomized trials, published October 27, 2026 in Diabetes, Obesity & Metabolism, which pooled the trials by CagriSema dose and by comparator.

A pooled analysis, not a new trial. The paper combines published and registered randomized trials; it does not test CagriSema itself. This article reports its abstract, which does not list the six trials it included.

What the meta-analysis found

Kow, Zaihan, Ramachandram and Thiruchelvam searched PubMed, Embase, CENTRAL and ClinicalTrials.gov through June 30, 2026 for randomized trials of CagriSema, the once-weekly combination of the amylin analog cagrilintide with semaglutide, in type 2 diabetes. Six trials were included, representing 4,554 potentially eligible participants, a figure the abstract gives as eligibility rather than as the number analysed. For HbA1c and body weight, the authors aligned results on the efficacy (trial-product) estimand where the trials reported it, and examined the treatment-policy estimates in sensitivity analyses. They used Bayesian random-effects models and report posterior medians with 95% credible intervals (CrI).

Against placebo, CagriSema 2.4 mg lowered HbA1c by 1.87 percentage points more (95% CrI, -2.08 to -1.62) and body weight by 12.69 percentage points more (95% CrI, -13.78 to -11.61).

Against semaglutide alone

The comparison most readers want is with semaglutide 2.4 mg on its own, the same dose of semaglutide that CagriSema contains. There, the extra HbA1c reduction was -0.21 percentage points, with a 95% credible interval of -0.62 to 0.11. Because that interval includes zero, the authors call the glycaemic advantage “modest and uncertain.” The extra weight reduction was -5.84 percentage points (95% CrI, -10.08 to -2.15), an interval that stays below zero, and the authors describe it as remaining probable.

Their conclusion: CagriSema’s “incremental advantage over dose-matched semaglutide is more evident for body-weight reduction.” Put plainly, in this pooling, adding cagrilintide to semaglutide bought weight loss, and the glycaemic gain could not be distinguished from none.

Side effects and discontinuation

Against placebo, gastrointestinal adverse events were more common with CagriSema (risk ratio 2.27; 95% CrI, 1.81 to 3.00), as was stopping treatment because of an adverse event (risk ratio 3.16; 95% CrI, 1.50 to 6.87). The estimates against semaglutide were less precise, and the authors conclude that comparative gastrointestinal tolerability and discontinuation risk “remain uncertain.”

How it relates to the ENDO 2026 poster

Prof. Peptide’s ENDO 2026 recap covered a different CagriSema meta-analysis, poster SUN-726 by Burkhardt da Silveira and colleagues, which pooled trials in obesity. That page did not quote pooled numbers because they could not be confirmed against a primary source. This paper is not that poster published: its population is type 2 diabetes and its authors are different. It does, however, give confirmable pooled effect sizes from a peer-reviewed source, which the obesity poster could not.

What this is, and isn’t

This is a report on one meta-analysis, read from its abstract. It is independent secondary research, not data released by the drug’s maker. CagriSema is an investigational combination and is not FDA-approved. Nothing here is medical advice, a dosing recommendation or a treatment comparison for any individual.

Sources

This article is for informational and educational purposes only and does not constitute medical advice. It reports the findings of one published meta-analysis from its abstract. CagriSema is investigational and not approved by the FDA.

Checked and updated